Brain uptake of iodine-131 metaiodobenzylguanidine following therapy of malignant pheochromocytoma

Clinical Nuclear Medicine

Volumn 23, Issue 7, 1998, Pages 441-445

  Dwamena, Ben A ^a   Zempel, Shirley ^a   Klopper, Johannes F ^b   Van Heerden, Barend ^b   Wieland, Don ^a   Shapiro, Brahm ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

I 131 MIBG; Intracranial Uptake; Metaiodobenzylguanidine; Pheochromocytoma; Posttherapy Imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ADRENALIN; METADRENALIN; NORADRENALIN;

ADOLESCENT; ADRENALIN BLOOD LEVEL; ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN SCINTISCANNING; CATECHOLAMINE URINE LEVEL; CEREBELLUM; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NORADRENALIN BLOOD LEVEL; PHEOCHROMOCYTOMA;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADRENERGIC AGONISTS; ADRENERGIC ALPHA-AGONISTS; ADULT; AGE FACTORS; AGED; BLOOD-BRAIN BARRIER; BODY MASS INDEX; BRAIN; CEREBELLUM; EPINEPHRINE; EVALUATION STUDIES; FEMALE; HUMANS; MALE; METANEPHRINE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NOREPINEPHRINE; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SEX FACTORS; SINGLE-BLIND METHOD;

EID: 0031683713     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199807000-00009     Document Type: Article

References (31)

1. Nakajo M, Shapiro B, Copp J, et al: The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-13]iodobenzylguanidine (I-131 MIBG) in man: Evaluation by scintiaraphy. J Nucl Med 24:672, 1483.
2. Parisi M, Sandler E, Hattner R: The biodistribution of metaiodobenzylguanidine. Semin Nucl Med 22:46, 1992.
3. McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM: Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 15:132, 1985.
4. McEwan AJ, Wyeth P, Ackery D: Radioiodinated iodobenzylguanidines for diagnosis and therapy. Int J Rad Appl Instrum [A] 37:765, 1986.
5. Hattner RS, Pounds TR, Matthay KK: Normal cerehellar MIBG localization. Implications in the interpretation of delayed scans. Clin Nucl Med 19:985, 1994.
6. Bomanji J, Moyes J, Huneidi AH, et al: Cerebral uptake of MIBG: Adrenoceptors visualized? Nucl Med Commun 12:3, 1991.
7. Guilloteau D, Huguet F, Chalon S, et al: MIBG and catecholamine storage in the brain: An in vitro study. Int J Rad Appl Instrum [B] 15:723, 1988.
8. 131I]metaiodobenzylguanidine: Results from ten years of experience. J Nucl Biol Med 35:269, 1991.
9. Shapiro B: Imaging of catecholamine-secreting tumors: Uses of MIBG in diagnosis and treatment. Bailliere's Clin Endocrinol Metab 7:491, 1993.
10. Sisson JC, Frager MS, Valk TW, et al: Scintigraphic localization of pheochromocytoma. N Engl J Med 305:12, 1981.
11. Sisson J, Shapiro B, Beierwaltes WH, et al: Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans Assoc Am Physicians 96:209, 1983.
12. 131I-metaiodobenzylguanidine. CA Cancer J Clin 34:86, 1984.
13. Sisson J, Shapiro B, Beierwaltes W, et al: Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 24: 197, 1984.
14. 131I-metaiodobenzylguanidine. Results from ten years of experience. J Nucl Biol Med 35:269, 1991.
15. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 33:159, 1977.
16. 131I MIBG scintigraphy in diagnosing pheochromocytoma. AJR Am J Roentgenol 141:719, 1983.
17. Glowniak JV, Shapiro B, Sisson JC, et al: Familial extra-adrenal pheochromocytoma. A new syndrome. Arch Intern Med 145: 257, 1985.
18. Shapiro B, Sisson J, Kalff V, et al: The location of middle mediastinal pheochromocytomas. J Thorac Cardiovasc Surg 87:814, 1984.
19. 131I-metaiodohenzylguanidine. Ann Intern Med 94:762, 1981.
20. Shapiro B, Copp J, Sisson J, Eyre P, Wallis J, Beierwaltes W: 131-I-metaiodobenzylguanidine for the locating of suspected pheochromocytoma: Experience in 400 cases (441 studies). J Nucl Med 26:576, 1985
21. Shulkin BL, Shapiro B, Hutchinson RJ: Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma [see comments]. J Nucl Med 33:1735, 1992.
22. Tobes M, Jaques S, Wieland D, Sisson J: Effect of uptake-one inhibitors on reuptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 26:897, 1985.
23. Gasnier B, Roisin MP, Scherman D, Coornaert S, Desplanches G, Henry JP: Uptake of metaiodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol 29:275, 1986.
24. Guilloteau D, Baulieu JL, Huguet F, et al: Meta-iodobenzylguanidine adrenal medulla localization: Autoradiographic and pharmacologic studies. Eur J Nucl Med 9:278, 1984.
25. Schäfer G: Guanidines and biguanides. Pharmacol Ther 9:275, 1990.
26. Scherman D, Gasnier B, Jaudon P, Henry J-P: Hydrophobicity of the tetrabenazine binding site of the chromaffin granule monamine transporter. Mol Pharmacol 33:72, 1988.
27. Oldendorf WM: Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med 147:813, 1974.
28. Mangner TJ, Tobes MC, Wieland DW, Sisson JC, Shapiro B: Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma. J Nucl Med 27:37, 1986.
29. Wafelman AR, Hoefnagel CA, Maes RAA, Beijnen JH: Bioanalysis of radioiodine-labelled metaiodobenzylguanidine, its metabolites, and free radioiodine in body fluid. Europ J Pharmaceut Sci 5:97, 1997.
30. 131I]iodobenzylguanidine (I-131 MIBG) and circulating catecholamines in suspected pheochromocytoma. J Nucl Med 24: 1127, 1983.
31. 131I]iodobenzylguanidine. J Nucl Med 25:2, 1984.